MediciNova, Inc. (MNOV)
NASDAQ: MNOV · IEX Real-Time Price · USD
1.340
-0.060 (-4.29%)
At close: Jul 19, 2024, 4:00 PM
1.360
+0.020 (1.49%)
Pre-market: Jul 22, 2024, 8:57 AM EDT
MediciNova Employees
MediciNova had 13 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$76,923
Profits / Employee
-$646,810
Market Cap
65.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Burning Rock Biotech | 786 |
Prenetics Global | 324 |
Celularity | 225 |
Pro-Dex | 146 |
BioLineRx | 79 |
VSee Lab/iDoc Virtual Telehealth Solutions, Inc. | 40 |
Entera Bio | 18 |
Milestone Scientific | 17 |
MNOV News
- 4 weeks ago - MediciNova Chief Business Officer David H. Crean, Ph.D. - GlobeNewsWire
- 6 weeks ago - MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer - GlobeNewsWire
- 7 weeks ago - MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 - GlobeNewsWire
- 7 weeks ago - MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions - GlobeNewsWire
- 2 months ago - MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer - GlobeNewsWire
- 2 months ago - MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 2 months ago - MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) - GlobeNewsWire
- 3 months ago - MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - GlobeNewsWire